Lung Cancer
Follow
Find
1.0K views | +0 today
Lung Cancer
News and Updates about Lung Cancer treatments and research
Curated by Brian Shields
Your new post is loading...
Your new post is loading...
Scooped by Brian Shields
Scoop.it!

Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy for NSCLC - Chemotherapy Advisor

Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy for NSCLC - Chemotherapy Advisor | Lung Cancer | Scoop.it
Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Brian Shields's insight:

Nice update on an important trial.

more...
No comment yet.
Rescooped by Brian Shields from Biomarkers and Personalized Medicine
Scoop.it!

Effectively targeting KRAS in lung cancer with a MEK inhibitor

Effectively targeting KRAS in lung cancer with a MEK inhibitor | Lung Cancer | Scoop.it

Exciting article from Sally Church reviewing a potential breakthrough in the treatment of NSCLC with KRAS mutations.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Lung Cancer at ASCO: Latest Trial Results and Emerging Therapies - Cancer Network

Lung Cancer at ASCO: Latest Trial Results and Emerging Therapies
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

This important article reviews the role of Exon-19 insertions as important markers of sensitivuty to EGFR-TKI therapy.  These mutations are poorly described and may be missing from mutation-specific assays.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

2011 Highlights in Lung Cancer, by Dr. Jared Weiss, Part 1: The EGFR Axis | GRACE :: Lung Cancer

2011 Highlights in Lung Cancer, by Dr. Jared Weiss, Part 1: The EGFR Axis | GRACE :: Lung Cancer | Lung Cancer | Scoop.it

This is a great resource for obtaining a status on current treaments in lung cancer and the status of research as well.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Peregrine Pharma Cancer Drug Unmasked by Independent Review - TheStreet.com

Peregrine Pharma Cancer Drug Unmasked by Independent Review. TheStreet.com(TheStreet) --Peregrine Pharmaceuticals'(PPHM) experimental lung cancer drug bavituximab looks like a bust.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Calallen Cancer Doctor Surprised, Upset By FDA Raid - KRIS Corpus Christi News

Calallen Cancer Doctor Surprised, Upset By FDA Raid - KRIS Corpus Christi News | Lung Cancer | Scoop.it
Cancer Doctor Surprised, Upset By FDA. South Texas Comprehensive Cancer Centers, operated by Dr.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Lung Cancer Screening Trial Helps First Patient « VICC News ...

Lung Cancer Screening Trial Helps First Patient « VICC News ... | Lung Cancer | Scoop.it
Kathy Leiser first heard about Vanderbilt-Ingram Cancer Center's lung cancer screening trial through a sponsorship ad on WPLN radio last summer. The Nashville office technology saleswoman and grandmother of three had ...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Study links heavy diesel exhaust to lung cancer - CTV.ca

Study links heavy diesel exhaust to lung cancer - CTV.ca | Lung Cancer | Scoop.it
Los Angeles TimesStudy links heavy diesel exhaust to lung cancerCTV.caAP WASHINGTON — There's new evidence that exposure to exhaust from diesel engines increases the risk of lung cancer.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

The IN VIVO Blog: Pfizer's Dolsten Sees a Bright Future for Xalkori and Pfizer Oncology

The IN VIVO Blog: Pfizer's Dolsten Sees a Bright Future for Xalkori and Pfizer Oncology | Lung Cancer | Scoop.it

"During a fireside chat at the BIOCEO meeting in New York this week, Pfizer’s president of worldwide R&D Mikael Dolsten ranged over the company’s R&D spend (down!), FDA filings (up!), and externalization initiatives (off the scale). He also offered his view on the more transformative products in Pfizer’s late-stage lineup: bullish on tofacitinib and Prevnar 13, inscrutable on bapineuzumab.


But his comments on Pfizer’s budding oncology franchise caught this blogger’s ear. Dolsten rightly highlighted Pfizer oncology’s strengths in tyrosine kinase biology, mentioning the recent launches of Xalkori for advanced NSCLC and Inlyta for advanced renal cell carcinoma, and also bragged about Pfizer’s emergence as a “significant player” in antibody conjugates..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Cynvenio Awarded Two SBIR Contracts to Develop Lung Cancer Assays Using CTC ... - Genetic Engineering News

Cynvenio Awarded Two SBIR Contracts to Develop Lung Cancer Assays Using CTC ... - Genetic Engineering News | Lung Cancer | Scoop.it

"Cynvenio Biosystems received two $195,000 Phase I Small Business Innovation Research (SBIR) contracts from the National Cancer Institute to fund the development of blood-based lung cancer assays based on its circulating tumor cell (CTC) technology. The firm in addition raised $1.2 million from existing shareholders, as part of a committed $2 million financing.


Under the first SBIR contract Cynvenio aims to develop a LiquidBiopsy™ blood test and diagnostic device that isolates CTCs from peripheral blood, to enable analysis of an individual patient’s lung cancer mutations without the need to take a tumor biopsy. The second contract is centered on development of a CTC-based drug resistance assay that detects the T790M EGFR mutation in lung tumors. The firm says this mutation is responsible for about 50% of cases of resistance to EGFR inhibitors."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Retreatment with erlotinib: Regain of TKI sensi... [Eur J Cancer. 2011] - PubMed - NCBI

Retreatment with erlotinib: Regain of TKI sensi... [Eur J Cancer. 2011] - PubMed - NCBI | Lung Cancer | Scoop.it

"BACKGROUND:

Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially impressive response to EGFR-TKIs, patients with an activating EGFR mutation invariably relapse. For these patients few treatment options are available after additional progression during or after chemotherapy. The aim of this study is to examine the effect of retreatment with an EGFR-TKI after a drug holiday.

PATIENTS AND METHODS:

We retrospectively reviewed the medical records of 14 patients with stage IV NSCLC who progressed after long-term disease control with EGFR-TKI, who were subsequently treated with standard chemotherapy and at renewed progression retreated with EGFR-TKI.

RESULTS:

Fourteen patients (five male, nine female, median age 55 years (39-70 years) received retreatment with erlotinib. The median interval from the discontinuation of EGFR-TKI to the 2nd episode was 9.5 months (3-36 months). Before starting retreatment 36% (n=5) had a T790M mutation. Retreatment resulted in 36% (n=5) partial response, 50% stable disease (n=7) and 14% progressive disease (n=2). Among patients with a T790M mutation this number was two, one and two, respectively. Seven patients are still on therapy without signs of progression. Median follow up is 9 months (1.5-16+months) and median PFS is 6.5 months (1-16+months).

CONCLUSION:

Our findings suggest that retreatment with erlotinib is an option for patients with NSCLC who initially benefited from previous EGFR-TKI treatment and progressed after standard cytotoxic chemotherapy."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Delays in the Diagnosis of Lung Cancer

Delays in the Diagnosis of Lung Cancer | Lung Cancer | Scoop.it

"A common theme among people I talk with who have lung cancer is how long it took to be diagnosed. Sometimes the delays I hear about are fairly short - the specialist was busy for a week and a half before they could get in..."

more...
No comment yet.
Suggested by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Molecular Targeted Agents and Biologic Therapies for Lung Ca... : Journal of Thoracic Oncology

Molecular Targeted Agents and Biologic Therapies for Lung Ca... : Journal of Thoracic Oncology | Lung Cancer | Scoop.it

"Tabulated below are “targeted” or novel agents that are being or have been evaluated in non-small cell lung cancer and small cell lung cancer. Only compounds that have entered clinical trials have been listed. The compounds are listed by class, and within each class, they are listed in the order of their phase of clinical development, with those in the latest phase being listed first"

Brian Shields's insight:

Excellent resource for the current status of targeted therapies in NSCLC

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

NYT: Large lung cancer study suggests targeted treatment

NYT: Large lung cancer study suggests targeted treatment | Lung Cancer | Scoop.it
The first large and comprehensive study of the genetics of a common lung cancer finds that more than half the tumors from that cancer have mutations that might be treated by new drugs that are already in the pipeline or that could be easily...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Extra copies of EGFR gene signal poor prognosis for vulvar cancer - Massachusetts General Hospital, Boston, MA

Extra copies of EGFR gene signal poor prognosis for vulvar cancer - Massachusetts General Hospital, Boston, MA | Lung Cancer | Scoop.it
MGH researchers report that women with vulvar carcinoma whose tumors have extra copies of the EGFR gene are at increased risk of dying from their cancer, information that could indentify patients who should be treated with targeted therapy drugs.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Lung Cancer Highlights, 2011 by Dr. Weiss, Part 2: ALK and other New Molecular Targets | GRACE :: Lung Cancer

Lung Cancer Highlights, 2011 by Dr. Weiss, Part 2: ALK and other New Molecular Targets | GRACE :: Lung Cancer | Lung Cancer | Scoop.it
Focus on EML4-ALK & ALK rearrangements in NSCLC, lung cancer & crizotinib (XALKORI) as targeted therapy. Also discussion of ROS-1 and crizotinib for this group.
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Drug Resistance in Lung Cancer Treatment - dailyRx

Drug Resistance in Lung Cancer Treatment - dailyRx | Lung Cancer | Scoop.it
Drug Resistance in Lung Cancer TreatmentdailyRxFuture testing for the presence of these mutations in lung cancer patients may help oncologists avoid losing valuable time when treating patients with resistant cancers, focusing on treatments that...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

New Study Questions The Effectiveness Of Avastin - Doctor Tipster

New Study Questions The Effectiveness Of Avastin - Doctor Tipster | Lung Cancer | Scoop.it
New Study Questions The Effectiveness Of Avastin. These discoveries, made by scientists at Johns Hopkins University School of Medicine, dispute the effectiveness of current treatments against cancer, such as Avastin...
more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Pha...

"Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo-controlled trial assessed whether vandetanib conferred an overall survival benefit in patients with advanced non–small-cell lung cancer (NSCLC) after prior treatment with an EGFR tyrosine kinase inhibitor and one or two chemotherapy regimens."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Does maintenance pemetrexed maintain quality of life? : The Lancet Oncology

Does maintenance pemetrexed maintain quality of life?. By - Thomas E Stinchcombe, David Cella ([Comment] Does maintenance pemetrexed maintain quality of life?
more...
No comment yet.
Rescooped by Brian Shields from Biomarkers and Personalized Medicine
Scoop.it!

Roche says fake Avastin found in Syria in 2009 - Health - Life & Style - Ahram Online

Article highlights the dangers of counterfeit medicines for high priced agents in the global community.

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Medical News:Radiation Gets Nod over Surgery in Early NSCLC - in Oncology, Lung Cancer from MedPage Today

"Patients with severe chronic obstructive pulmonary disease and early-stage lung cancer had better 30-day survival when treated with stereotactic body radiotherapy (SBRT) instead of surgery, investigators reported.


Data from a single-institution cohort and a systematic literature review produced a one-year actuarial survival of 79% to 95% and three-year survival of 43% to 70% for SBRT. Surgically treated patients had an actuarial survival of 45% to 86% at one year and 31% to 66% at three years..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

National Cancer Institute Awards Two Lung Cancer Circulating Tumor Cell (CTC) Development Contracts to Cynvenio Biosystems, Inc.

"Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research, personalized medicine and the molecular diagnostics of cancer, today announced that the National Cancer Institute (NCI) awarded two Small Business Innovative Research (SBIR) contracts to develop novel lung cancer tests based on the isolation of mutation-bearing Circulating Tumor Cells (CTCs) from whole blood. The NCI awarded Phase I funding of $195,000 for each contract, and Cynvenio will be eligible to apply for Phase II funding of $1.5 million (for each contract) when the Phase I objectives are successfully achieved. Cynvenio's core technology was independently verified against clinical patient samples in 2011. The company also announced that it has received an additional $1.2 million from existing shareholders as part of a fully committed $2.0 million financing authorized by its board of directors..."

more...
No comment yet.
Scooped by Brian Shields
Scoop.it!

Study identified source of crizotinib resistance in ALK-positive lung cancer | HemOncToday

Study identified source of crizotinib resistance in ALK-positive lung cancer | HemOncToday | Lung Cancer | Scoop.it

Somatic kinase domain mutations, gene fusion and the emergence of separate oncogenic drivers are factors responsible for the observed crizotinib resistance ...

more...
No comment yet.